Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
Applied Therapeutics Announces $100 Million Private Placement
08:05am, Wednesday, 28'th Feb 2024
Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors
PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clini
Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
03:25pm, Friday, 16'th Feb 2024
Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if
Applied Therapeutics stock falters on heart disease trial failure
11:29am, Friday, 05'th Jan 2024
Applied Therapeutics shares plunged almost 35% after the biotechnology firm reported disappointing results from its Phase 3 heart disease trial. The company reported that its ARISE-HF trial of drug c
Why Is Applied Therapeutics (APLT) Stock Down 30% Today?
09:23am, Friday, 05'th Jan 2024
Applied Therapeutics (NASDAQ: APLT ) stock is falling on Friday following the release of Phase 3 clinical trial data from the clinical-stage biopharmaceutical company. This data comes from Applied Th
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
04:05pm, Thursday, 04'th Jan 2024
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months
Applied Therapeutics: Multiple Inflection Points Could Generate Substantial Value
05:19am, Thursday, 04'th Jan 2024
EMA validated and accepted the regulatory application of govorestat for the treatment of patients with galactosemia; the FDA has a 60-day review period to look at the application for validation and ac
3 Penny Stocks To Buy According To Insiders In December
03:36pm, Thursday, 07'th Dec 2023
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in
Applied Therapeutics Reports Third Quarter 2023 Financial Results
07:30am, Thursday, 09'th Nov 2023
Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
07:00am, Wednesday, 01'st Nov 2023
Forum to be Webcast Live Topline Phase 3 Data Readout from ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy On Track for 4Q 2023 NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Th
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
07:00am, Thursday, 28'th Sep 2023
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole
Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)
04:28am, Thursday, 17'th Aug 2023
Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potentia
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
7 Hot Growth Stocks Poised to Triple in 2023
02:24pm, Friday, 05'th May 2023
Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear.
